



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/036,645	03/06/1998	DAVID BERD	1225/0C675.U	6219
28977	7590	05/11/2005	EXAMINER	
MORGAN, LEWIS & BOCKIUS LLP 1701 MARKET STREET PHILADELPHIA, PA 19103-2921			MYERS, CARLA J	
			ART UNIT	PAPER NUMBER
			1634	

DATE MAILED: 05/11/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

15

Office Action Summary	Application No.	Applicant(s)	
	09/036,645	BERD, DAVID	
	Examiner	Art Unit	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 09 October 2001.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1,2 and 21-31 is/are pending in the application.
 - 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1,2 and 21-31 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

<ol style="list-style-type: none"> 1)<input checked="" type="checkbox"/> Notice of References Cited (PTO-892) 2)<input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) 3)<input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date _____. 	<ol style="list-style-type: none"> 4)<input type="checkbox"/> Interview Summary (PTO-413) Paper No(s)/Mail Date. _____. 5)<input type="checkbox"/> Notice of Informal Patent Application (PTO-152) 6)<input type="checkbox"/> Other: _____.
--	--

DETAILED ACTION

1. This action is in response to the amendment filed October 9, 2001. Claims 1-2 and 21-31 are pending. This application was withdrawn from issue on July 31, 2001. This action contains new grounds of rejection and is made non-final.
2. The examiner reviewing your application at the PTO has changed. To aid in correlating papers in this application, all further correspondence regarding this application should be directed to examiner Carla Myers.

Oath/Declaration

3. The reissue oath/declaration filed with this application is defective because it fails to contain a statement that all errors which are being corrected in the reissue application up to the time of filing of the oath/declaration arose without any deceptive intention on the part of the applicant. See 37 CFR 1.175 and MPEP § 1414.

Further, the reissue oath/declaration filed with this application is defective because it fails to properly identify at least one error which is relied upon to support the reissue application. In particular, the original oath/declaration is missing the clause that the error arose without deceptive intent **“on the part of applicants.”** Additionally, the language in the present oath/declaration indicating that Applicant’s **“may have claimed more than”** they were entitled to claim is not sufficient. The oath/declaration must definitively and specifically state the error upon which the re-issue application is based. Lastly, the oath/declaration must point to the specific claim limitation that is being added or removed to correct the stated error. The present oath/declaration describes only the

Berd abstract and what it teaches but does not state how these teachings are related to any particular claim limitation.

4. Claims 1-2 and 21-31 are rejected as being based upon a defective reissue oath/declaration under 35 U.S.C. 251 as set forth above. See 37 CFR 1.175.

The nature of the defect(s) in the oath/declaration is set forth in the discussion above in this Office action.

Claim Objections

5. Claim 1 is objected to because of the following informalities:

In claim 1, "trinytrophenyl" should read "trinitrophenyl."

Claim Rejections - 35 USC § 103

6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 26-31 are rejected under 35 U.S.C. 103(a) as being unpatentable over Berd et al (Proceedings of the American Association for Cancer Research. March 1989. 30: page 382, abstract #1515) in view of Berd (Cancer Investigation. 1988. 6(3): 337-349; previously cited in IDS of U.S. Patent No. 5,290,551).

Berd (1989) teaches that treatment of melanoma patients with cyclophosphamide (CY) followed by autologous vaccine induces delayed-type hypersensitivity to melanoma cells and in some cases regression of metastatic cancer. To enhance this treatment, Berd studied the effectiveness of administering hapten conjugated

autologous melanoma cells. The method of Berd comprises: (i) administering to a patient a low dose of cyclophosphamide; and (ii) 3 days following treatment with CY, injecting patients with a vaccine containing $10-25 \times 10^6$ autologous, irradiated melanoma cells mixed with Bacille Calmette-Guerin(BCG). Berd reports that in a study of melanoma patients, one patient developed erythema and swelling in the dermal metastases on her leg and lower abdomen, followed by ulceration and drainage of necrotic material and some level of regression of the metastases. A second patient also showed erythema and swelling of the skin of her lower abdomen and groin and a change in consistency from rock-hard tumor to fluctuant. A third patient exhibited moderate erythema. All 3 patients developed delayed-type hypersensitivity (DTH) against both DNCB and DNP-conjugated autologous lymphocytes. Berd concluded that "(a)lthough the results are preliminary, they suggest that this new strategy may represent a significant advance in the immunotherapy of human melanoma."

While Berd (1989) teaches that the patients were injected with the DNP-conjugated melanoma vaccine, Berd does not specifically teach that the injection was intradermal, or that the injection was made to 3 sites on an upper arm or leg.

However, Berd (1988) teaches methods of immunotherapy for human melanoma wherein $10-25 \times 10^6$ autologous melanoma cells mixed with BCG are injected intradermally into three sites on the patients upper arm or legs (see page 340, column 1). Berd reports that patients receiving CY and the melanoma vaccine developed DTH to tumor antigens (page 342, column 2). Three of the patients tested showed complete

remission, one partial remission and two had minor responses to the vaccine (page 344, column 2).

According, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have practiced the method of Berd (1989) by injecting the DPN-conjugated melanoma vaccine mixed with BCG intradermally to 3 contiguous sites on the patient's upper arm or leg because as taught by Berd (1988) this is a conventional means for administering the melanoma cancer vaccine and would have provided an effective route of administration.

With respect to the recitation in the claims of "wherein administration of said vaccine induces a delayed-type hypersensitivity (DTH) response against unmodified melanoma cells" it is considered to be a property of the vaccine of Berd that it is capable of inducing a DTH response against unmodified melanoma cells. Given that the vaccine of Berd is identical to the vaccine of the present invention, in the absence of evidence to the contrary, the vaccine of Berd (1989) is expected to function similarly to the present vaccine. Therefore, the resulting method of intradermally injecting the DNP-vaccine of Berd (1989) would have necessarily resulted in a DTH response against unmodified melanoma cells.

With respect to claims 28 and 29, Berd (1989) does not characterize the melanoma patients that were treated with the DNP-conjugated melanoma vaccine and thereby does not specifically teach administering the vaccine to post-surgical melanoma patients or to stage 4 melanoma patients. However, Berd (1988; see, e.g., page 340) teaches administering melanoma vaccines to patients post-surgically and to patients

with extensive metastatic disease. Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have administered the DNP- conjugated melanoma vaccine of Berd (1989) to patients post-surgically and to stage 4 melanoma patients in order to have provided an effective means of treatment for those patients most in need of therapy.

With respect to claim 30, Berd (1989) teaches that of the four patients studied, three "developed a striking inflammatory response in tumor masses after 2 vaccine treatments (8 weeks)." Further, Berd (1988; page 340) teaches repeating the vaccine treatment every 28 days. The number of vaccine treatments ranged from 1 to 15, with a median of 4 treatments. Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have intradermally administered the DNP-conjugated melanoma vaccine every 4 weeks because this would have boosted the response to the vaccine and thereby would have increased the effectiveness of the therapy.

With respect to claim 31, Berd (1989) does not teach that the autologous melanoma cells are cryopreserved. However, Berd (1988; page 340) teaches that the tumor masses are removed from the patient and tumor cells are cryopreserved in liquid nitrogen until needed. Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have used cryopreserved autologous melanoma cells because this would have provided a more convenient means of administering the therapy since such cells could be frozen and stored and then administered at 4 week intervals.

7. Claims 26-31 are rejected under 35 U.S.C. 103(a) as being unpatentable over Berd et al (Proceedings of the American Association for Cancer Research. March 1990. 31: page 279, abstract #1654) in view of Berd (1988).

Berd (1990) teaches a method of treating metastatic melanoma wherein the method comprises: (i) administering to a melanoma patient a low dose of cyclophosphamide; and (ii) 3 days following treatment with CY, injecting patients with a vaccine containing $10-25 \times 10^6$ autologous, irradiated melanoma cells. Berd reports that the vaccine induced a "striking inflammatory response in 11/15 patients, consisting of erythema, swelling, warmth and tenderness around tumor masses." Further, 92% of the patients developed DTH to the DNP-conjugated melanoma cells. The reference states that the "DNP-vaccine seems to induce a degree of anti-melanoma immunity not seen with previously tested immunotherapy."

While Berd (1990) teaches that the patients were injected with the DNP-conjugated melanoma vaccine, Berd does not specifically teach that the injection was intradermal, or that the injection was made to 3 sites on an upper arm or leg.

However, Berd (1988) teaches methods of immunotherapy for human melanoma wherein $10-25 \times 10^6$ autologous melanoma cells mixed with BCG are injected intradermally into the three sites on the patients upper arm or legs (see page 340, column 1). Berd (1988) reports that patients receiving CY and the melanoma vaccine developed DTH to tumor antigens (page 342, column 2). Three of the patients tested showed complete remission, one partial remission and two had minor responses to the vaccine (page 344, column 2).

According, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have practiced the method of Berd (1990) by injecting the DPN-conjugated melanoma vaccine mixed with BCG intradermally to 3 contiguous sites on the patient's upper arm or leg because as taught by Berd (1988) this is a conventional means for administering the melanoma cancer vaccine and would have provided an effective route of administration.

With respect to the recitation in the claims of "wherein administration of said vaccine induces a delayed-type hypersensitivity (DTH) response against unmodified melanoma cells" it is considered to be a property of the vaccine of Berd that it is capable of inducing a DTH response against unmodified melanoma cells. Given that the vaccine of Berd is identical to the vaccine of the present invention, in the absence of evidence to the contrary, the vaccine of Berd (1990) is expected to function similarly to the present vaccine. Therefore, the resulting method of intradermally injecting the DNP-vaccine of Berd (1990) would have necessarily resulted in a DTH response against unmodified melanoma cells.

Further, Berd (1990) does not teach that the vaccine is mixed with BCG. However, Berd (1988; page 340) teaches mixing the melanoma vaccine with the immunological adjuvant BCG. Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have mixed the DNP-conjugated melanoma vaccine with the immunological adjuvant BCG in order to have further enhanced the patient's immune response.

With respect to claims 28 and 29, Berd (1990) does not characterize the melanoma patients that were treated with the DNP-conjugated melanoma vaccine and thereby does not specifically teach administering the vaccine to post-surgical melanoma patients or to stage 4 melanoma patients. However, Berd (1988; see, e.g., page 340) teaches administering the melanoma vaccine to patients post-surgically and to patients with extensive metastatic disease. Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have administered the DNP- conjugated melanoma vaccine of Berd (1990) to patients post-surgically and to stage 4 melanoma patients in order to have provided an effective means of treatment for those patients most in need of therapy.

With respect to claim 30, Berd (1990) teaches that patients were injected with the DNP-conjugated melanoma vaccine every 4 weeks.

With respect to claim 31, Berd (1990) does not teach that the autologous melanoma cells are cryopreserved. However, Berd (1988; page 340) teaches that the tumor masses are removed from the patient and tumor cells are cryopreserved in liquid nitrogen until needed. Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have used cryopreserved autologous melanoma cells because this would have provided a more convenient means of administering the therapy since such cells could be frozen and stored and then administered at 4 week intervals.

8. Claims 26-31 are rejected under 35 U.S.C. 103(a) as being unpatentable over Murphy et al (Laboratory Investigation. 1990. 62(1): 70A, abstract #412) in view of Berd (1988).

Murphy teaches a method of treating metastatic melanoma wherein the method comprises: (i) administering to a melanoma patient a low dose of cyclophosphamide; and (ii) 3 days following treatment with CY, injecting patients with a vaccine containing $10-25 \times 10^6$ autologous, irradiated melanoma cells mixed with Bacille Calmette-Guerin(BCG). Murphy reports that 7 patients showed clinical regression following treatment.

While Murphy teaches that the patients were injected with the DNP-conjugated melanoma vaccine, Murphy does not specifically teach that the injection was intradermal, or that the injection was made to 3 sites on an upper arm or leg.

However, Berd (1988) teaches methods of immunotherapy for human melanoma wherein $10-25 \times 10^6$ autologous melanoma cells mixed with BCG are injected intradermally into the three sites on the patients upper arm or legs (see page 340, column 1). Berd (1988) reports that patients receiving CY and the melanoma vaccine developed DTH to tumor antigens (page 342, column 2). Three of the patients tested showed complete remission, one partial remission and two had minor responses to the vaccine (page 344, column 2).

According, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have practiced the method of Murphy by injecting the DPN-conjugated melanoma vaccine mixed with BCG intradermally to 3 contiguous sites

on the patient's upper arm or leg because as taught by Berd (1988) this is a conventional means for administering the melanoma cancer vaccine and would have provided an effective route of administration.

With respect to the recitation in the claims of "wherein administration of said vaccine induces a delayed-type hypersensitivity (DTH) response against unmodified melanoma cells" it is considered to be a property of the vaccine of Berd that it is capable of inducing a DTH response against unmodified melanoma cells. Given that the vaccine of Murphy is identical to the vaccine of the present invention, in the absence of evidence to the contrary, the vaccine of Murphy is expected to function similarly to the present vaccine. Therefore, the resulting method of intradermally injecting the DNP-vaccine of Murphy would have necessarily resulted in a DTH response against unmodified melanoma cells.

With respect to claims 28 and 29, Murphy does not characterize the melanoma patients that were treated with the DNP-conjugated melanoma vaccine and thereby does not specifically teach administering the vaccine to post-surgical melanoma patients or to stage 4 melanoma patients. However, Berd (1988; see, e.g., page 340) teaches administering the melanoma vaccine to patients post-surgically and to patients with extensive metastatic disease. Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have administered the DNP- conjugated melanoma vaccine of Murphy to patients post-surgically and to stage 4 melanoma patients in order to have provided an effective means of treatment for those patients most in need of therapy.

With respect to claim 30, Murphy does not specifically teach that patients were injected with the DNP-conjugated melanoma vaccine every 4 weeks. However, Berd (1988a; page 340) teaches repeating the vaccine treatment every 28 days. The number of vaccine treatments ranged from 1 to 15, with a median of 4 treatments. Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have intradermally administered the DNP-conjugated melanoma vaccine every 4 weeks because this would have boosted the response to the vaccine and thereby would have increased the effectiveness of the therapy.

With respect to claim 31, Murphy does not teach that the autologous melanoma cells are cryopreserved. However, Berd (1988; page 340) teaches that the tumor masses are removed from the patient and tumor cells are cryopreserved in liquid nitrogen until needed. Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have used cryopreserved autologous melanoma cells because this would have provided a more convenient means of administering the therapy since such cells could be frozen and stored and then administered at 4 week intervals.

9. Claims 2 and 21-25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Berd et al (1989) in view of Berd (1988), as applied to claims 26-31 above, and further in view of Fujiwara (The Journal of Immunology. 1980. 124: 863-869).

The teachings of Berd (1989) and Berd (1988) are presented above. Berd (1989) teaches treating melanoma patients with a hapten conjugated melanoma vaccine, wherein the hapten is dinitrophenyl (DNP). Berd (1989) does not teach treating

melanoma patients with a hapten conjugated melanoma vaccine wherein the hapten is trinitrophenyl (TNP).

Fujiwara (page 864) teaches conjugating TNP to tumor cells and the use of TNP-conjugated tumor cells to treat tumors. The reference teaches that the TNP-conjugated tumor cells induced enhanced tumor-specific immunity leading to regression of growing tumor when administered following priming with TNP (see abstract and page 868).

Fujiwara teaches that the augmented immunity is due to the activity of cytotoxic T cells and T cells essential for tumor rejection.

In view of the teachings of Fujiwara of the effectiveness of TNP-conjugated tumor cells to augment immunity and enhance the tumor rejection response and in view of the known structural similarities between DNP and TNP, the ordinary artisan would have expected that TNP-conjugated melanoma cells could be substituted for DNP-conjugated melanoma cells in order to provide an effective means for treating melanoma.

Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have modified the method of Berd (1989) so as to have used TNP in place of DNP as the hapten in order to have provided an equally effective vaccine for treating melanoma.

10. Claims 2 and 21-25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Berd et al (1990) in view of Berd (1988), as applied to claims 26-31 above, and further in view of Fujiwara.

The teachings of Berd (1990) and Berd (1988) are presented above. Berd (1990). Berd (1990) does not teach treating melanoma patients with a hapten conjugated melanoma vaccine wherein the hapten is trinitrophenyl (TNP).

Fujiwara (page 864) teaches conjugating TNP to tumor cells and the use of TNP-conjugated tumor cells to treat tumors. The reference teaches that the TNP-conjugated tumor cells induced enhanced tumor-specific immunity leading to regression of growing tumor when administered following priming with TNP (see abstract and page 868). Fujiwara teaches that the augmented immunity is due to the activity of cytotoxic T cells and T cells essential for tumor rejection.

In view of the teachings of Fujiwara of the effectiveness of TNP-conjugated tumor cells to augment immunity and enhance the tumor rejection response and in view of the known structural similarities between DNP and TNP, the ordinary artisan would have expected that TNP-conjugated melanoma cells could be substituted for DNP-conjugated melanoma cells in order to provide an effective means for treating melanoma. Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have modified the method of Berd (1990) so as to have used TNP in place of DNP as the hapten in order to have provided an equally effective vaccine for treating melanoma.

11. Claims 2 and 21-25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Murphy in view of Berd (1988), as applied to claims 26-31 above, and further in view of Fujiwara.

The teachings of Murphy and Berd (1988) are presented above. Murphy teaches treating melanoma patients with a hapten conjugated melanoma vaccine, wherein the hapten is dinitrophenyl (DNP). Murphy does not teach treating melanoma patients with a hapten conjugated melanoma vaccine wherein the hapten is trinitrophenyl (TNP).

Fujiwara (page 864) teaches conjugating TNP to tumor cells and the use of TNP-conjugated tumor cells to treat tumors. The reference teaches that the TNP-conjugated tumor cells induced enhanced tumor-specific immunity leading to regression of growing tumor when administered following priming with TNP (see abstract and page 868). Fujiwara teaches that the augmented immunity is due to the activity of cytotoxic T cells and T cells essential for tumor rejection.

In view of the teachings of Fujiwara of the effectiveness of TNP-conjugated tumor cells to augment immunity and enhance the tumor rejection response and in view of the known structural similarities between DNP and TNP, the ordinary artisan would have expected that TNP-conjugated melanoma cells could be substituted for DNP-conjugated melanoma cells in order to provide an effective means for treating melanoma. Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have modified the method of Murphy so as to have used TNP in place of DNP as the hapten in order to have provided an equally effective vaccine for treating melanoma.

12. Claim 1 is rejected under 35 U.S.C. 103(a) as being unpatentable over Berd et al (1989) and Fujiwara.

The teachings of Berd (1989) are presented above. Berd (1989) teaches using a hapten conjugated melanoma vaccine to treat melanoma patients, wherein the hapten is dinitrophenyl (DNP). Berd (1989) does not teach a hapten conjugated melanoma vaccine wherein the hapten is trinitrophenyl (TNP).

Fujiwara (page 864) teaches conjugating TNP to tumor cells and the use of TNP-conjugated tumor cells to treat tumors. The reference teaches that the TNP-conjugated tumor cells induced enhanced tumor-specific immunity leading to regression of growing tumor when administered following priming with TNP (see abstract and page 868). Fujiwara teaches that the augmented immunity is due to the activity of cytotoxic T cells and T cells essential for tumor rejection.

In view of the teachings of Fujiwara of the effectiveness of TNP-conjugated tumor cells to augment immunity and enhance the tumor rejection response and in view of the known structural similarities between DNP and TNP, the ordinary artisan would have expected that TNP-conjugated melanoma cells could be substituted for DNP-conjugated melanoma cells in order to provide an effective means for treating melanoma. Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have modified the method of Berd (1989) so as to have used TNP in place of DNP as the hapten in order to have provided an equally effective vaccine for treating melanoma.

13. Claim 1 is rejected under 35 U.S.C. 103(a) as being unpatentable over Berd et al (1990) in view of Fujiwara.

The teachings of Berd (1990) are presented above. Berd (1990) teaches using a hapten conjugated melanoma vaccine to treat melanoma patients, wherein the hapten is dinitrophenyl (DNP). Berd (1990) does not teach a hapten conjugated melanoma vaccine wherein the hapten is trinitrophenyl (TNP).

Fujiwara (page 864) teaches conjugating TNP to tumor cells and the use of TNP-conjugated tumor cells to treat tumors. The reference teaches that the TNP-conjugated tumor cells induced enhanced tumor-specific immunity leading to regression of growing tumor when administered following priming with TNP (see abstract and page 868). Fujiwara teaches that the augmented immunity is due to the activity of cytotoxic T cells and T cells essential for tumor rejection.

In view of the teachings of Fujiwara of the effectiveness of TNP-conjugated tumor cells to augment immunity and enhance the tumor rejection response and in view of the known structural similarities between DNP and TNP, the ordinary artisan would have expected that TNP-conjugated melanoma cells could be substituted for DNP-conjugated melanoma cells in order to provide an effective means for treating melanoma. Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have modified the method of Berd (1990) so as to have used TNP in place of DNP as the hapten in order to have provided an equally effective vaccine for treating melanoma.

14. Claim 1 is rejected under 35 U.S.C. 103(a) as being unpatentable over Murphy in view of Fujiwara.

The teachings of Murphy are presented above. Murphy teaches using a hapten conjugated melanoma vaccine to treat melanoma patients, wherein the hapten is dinitrophenyl (DNP). Murphy does not teach a hapten conjugated melanoma vaccine wherein the hapten is trinitrophenyl (TNP).

Fujiwara (page 864) teaches conjugating TNP to tumor cells and the use of TNP-conjugated tumor cells to treat tumors. The reference teaches that the TNP-conjugated tumor cells induced enhanced tumor-specific immunity leading to regression of growing tumor when administered following priming with TNP (see abstract and page 868). Fujiwara teaches that the augmented immunity is due to the activity of cytotoxic T cells and T cells essential for tumor rejection.

In view of the teachings of Fujiwara of the effectiveness of TNP-conjugated tumor cells to augment immunity and enhance the tumor rejection response and in view of the known structural similarities between DNP and TNP, the ordinary artisan would have expected that TNP-conjugated melanoma cells could be substituted for DNP-conjugated melanoma cells in order to provide an effective means for treating melanoma. Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have modified the method of Murphy so as to have used TNP in place of DNP as the hapten in order to have provided an equally effective vaccine for treating melanoma.

RESPONSE TO ARGUMENTS:

15. While the claims in this application have not been previously rejected over Berd (1989), Berd (1990) or Murphy (1990), Applicants response of October 9, 2001 includes

arguments regarding the Berd (1989) abstract. Further, Applicants provide a 132 Declaration by Dr. Braun addressing the Berd (1989) abstract and a Fujiwara 1984 paper. Applicants arguments and the 132 Declaration have been fully considered but are not persuasive to overcome the rejections set forth above.

The response and 132 Declaration argue that the Berd abstract fails to teach that the DNP-vaccine would elicit a DTH response against unmodified tumor cells. However, given that the DNP-vaccine of Berd is structurally identical to the vaccine of the present invention, it is considered to be a property of the vaccine of Berd that this vaccine induces a DTH response against unmodified tumor cells. It is noted that Example 2 of the specification provides the same information set forth in the Berd (1989) abstract. Since the same patients were utilized and the same vaccine and methodology was employed, the results of such methods should also be the same – i.e., that the method of Berd also induces DTH to unmodified melanoma cells. There is no requirement for Berd to disclose that the vaccine has this property since the vaccine necessarily has this property.

Applicants assert that the “mere hapten-specific immune response as reported in the Berd Abstract (the DTH response to DNCB and DNP-conjugated lymphocytes) could not contribute to any long-term clinical benefit and would not, for example, protect against recurrence of cancer.” This argument has been fully considered but is not persuasive. It is first noted that claims 1 and 21 are drawn to vaccines and thereby the obviousness of the vaccine does not require a showing of long-term clinical benefits or protection against the recurrence of cancer. With respect to claims 2 and 22-31, the

claims also do not require that the methods provide a long-term clinical benefit or protection against recurrence of cancer since the claims require only the treatment of melanoma. Further, as discussed above, since the vaccine of Berd is identical to the vaccine of the present invention, in the absence of evidence to the contrary, the use of the vaccine of Berd will result in the same outcomes as that of the present invention, such as long term clinical benefits and protection against recurrence of cancer.

The response and the 132 Declaration assert that the ordinary artisan would not have expected that a response to TNP could be elicited from TNP-conjugated cells. This argument is not persuasive because Fujiwara teaches that TNP-conjugated tumor cells generate an immune response and enhance the rejection of tumor cells. Further, in view of the high level of structural similarity between the DNP and TNP haptens, the ordinary artisan would have expected that TNP could be used in place of DNP and would be equally effective at enhancing the immune response. It is noted that the present specification does not provide any data for TNP-conjugated melanoma vaccines or AED-conjugated melanoma vaccines. The teachings in the specification regarding TNP and AED are limited to a single sentence of: "Other useful haptens include TNP and AED which may be chemically linked to the tumor cells" (see column 3, lines 58-59 of '551). In addressing the enablement of the present invention, Applicants previously argued in the March 6, 1992 response of '551 that "Other haptens of the claimed invention, trinitrophenyl and N-iodoacetyl-N'-(5 sulfonic 1-naphthyl) ethylene diamine, would be expected to behave similarly to DNP" and conclude that the selection and use of alternative haptens, such as TNP, would have been well within the skill of the art.

The specification has not established any unexpected results associated with the use of TNP and has acknowledged the obviousness of using alternative haptens with the expectation that they will behave similarly to DNP. Accordingly, the ordinary artisan also recognizing the similarity in structure between DNP and TNP and apprised of the teachings of Fujiwara of the use of TNP as a hapten to augment the immune response to tumors, would have been motivated to have used, and would have had more than a reasonable expectation of success at using TNP-conjugated melanoma vaccines for the treatment of melanoma.

The response and the 132 Declaration assert that the Berd abstract does not provide sufficient details as to how to practice a method of treatment using the hapten-conjugated tumor vaccine. The 132 Declaration argues that the Berd abstract does not teach whether to use whole cells or extracts, whether to use adjuvants or cytokines or whether an antitumor response would lead to autoimmunity. However, the Berd abstract does in fact teach the use of $10-25 \times 10^6$ DNP-conjugated autologous melanoma **cells**. Thereby, the reference clearly teaches the use of cells and not cell extracts. Further, the reference teaches mixing the cells with BCG and thereby clearly teaches the use of an immunological adjuvant, rather than the use of cytokines. The Declaration asserts that the reference is ambiguous in its statement to use 10-25 million cells and that one would not know whether to use the cells as single injection or divided into multiple sites. It is also asserted that one would not know how to administer the vaccine (e.g., whether the vaccine should be administered intradermally, subcutaneously, or intramuscularly). Further, the declaration asserts that the ratio of tumor cells to BCG is not provided and

that the statement regarding the schedule of administration in the Berd 1989 abstract is ambiguous. However, the above rejections are made over the combination of Berd (1989) and Berd (1988). The Berd 1988 reference provides extensive details on how to administer melanoma cancer vaccines. In particular, Berd teaches that the vaccine comprising 10-25 million tumor cells mixed with .8 to 2.6million viable BCG organisms is administered intradermally to three sites on the arms or legs at 4 week intervals (page 340). The teachings of Berd (1988) in combination with the Berd 1989 abstract (or Berd 1990 or Murphy abstracts) provide sufficient guidance to enable the skilled artisan to practice the claimed invention. Further, it is noted that the present claims are not limited to methods in which a particular ratio of tumor cells to BCG is employed or in which a specific dosage is injected at each site.

The 132 Declaration states that a review article by Hanna and Hoover does not address the Berd 1989 abstract. It is stated that if the data in the Berd 1989 abstract had been considered to be clinically meaningful, the approach would have been considered in the review. This argument has been fully considered but is not persuasive. The opinion of the declarant is not supported by any factual evidence. The obviousness of an invention is not evaluated in terms of whether others in the art choose to provide a summary of an inventor's abstract in a review article. As set forth in the above rejection, the prior art when considered as a whole provides both the motivation and the guidance to lead the ordinary artisan to the claimed invention. The Berd 1989 abstract teaches that the administration of the DNP-conjugated melanoma vaccine did provide a clinically relevant result in 3 of 4 patients studied. Further, Berd

1988 provides extensive guidance as to how administer melanoma vaccines. Obviousness does not require absolute predictability but only the reasonable expectation of success. See In re Merck and Company Inc., 800 F. 2d 1091, 231 USPQ 375 (Fed. Cir. 1986) and In re O'Farrell, 7 USPQ2d 1673 (Fed. Cir. 1988). Thereby, the claimed invention would have been obvious to and well within the ordinary skill of the art at the time the invention was made.

Double Patenting

16. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claim 1 is rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 47, 65-67, 69-72, 74-77 of copending Application No. 08/203,004. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of '004 recite a method of treatment using a composition comprising each of the components of the presently claimed vaccine. In particular, the claims of '004 recite a method using a composition comprising autologous melanoma cells conjugated to a hapten, and mixed

with an immunological adjuvant, wherein the hapten is TNP or AED and the adjuvant is BCG. The claims of '004 recite that the cells have been rendered incapable of growing in the body of a human upon rejection therein, whereas the present claims specify that the cells are irradiated. However, the specification of '004 (page 12) states that "(t)umor cells or extracts are irradiated at 2500 cGy to prevent the cells from growing after injection." Since the claims of '004 are read in light of the specification, it is clear that the claims of '004 encompass irradiated melanoma cells. Accordingly, the claims of '004 disclose a composition comprising each of the components of the presently claimed vaccine and thereby render the presently claimed vaccine obvious.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

17. Claims 2 and 21-31 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 47, 65-72, 74-77 of copending Application No. 08/203,004 in view of Berd (1988). Although the conflicting claims are not identical, they are not patentably distinct from each other because both the present claims and the claims of '004 recite vaccines and a method of treatment using a vaccine, wherein the vaccine comprises autologous melanoma cells conjugated to a hapten, and mixed with the immunological adjuvant. In particular, the hapten is DNP, TNP or AED and the adjuvant is BCG. The present claims and the claims of '004 also both encompass methods in which the cyclophosphamide is administered to the patient prior to administering the melanoma vaccine. The claims of '004 recite that the cells have been rendered incapable of growing in the body of a

human upon rejection therein, whereas the present claims specify that the cells are irradiated. However, the specification of '004 (page 12) states that "(t)umor cells or extracts are irradiated at 2500 cGy to prevent the cells from growing after injection." Since the claims of '004 are read in light of the specification, it is clear that the claims of '004 encompass irradiated melanoma cells. The claims of '004 differ from the present claims in that they do not recite that the vaccine is injected intradermally or that the injection was made to 3 sites on an upper arm or leg.

However, Berd (1988) teaches methods of immunotherapy for human melanoma wherein $10-25 \times 10^6$ autologous melanoma cells mixed with BCG are injected intradermally into three sites on the patients upper arm or legs (see page 340, column 1). Berd reports that patients receiving CY and the melanoma vaccine developed DTH to tumor antigens (page 342, column 2). Three of the patients tested showed complete remission, one partial remission and two had minor responses to the vaccine (page 344, column 2). According, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have practiced the method of '004 by injecting the hapten conjugated melanoma vaccine mixed with BCG intradermally to 3 contiguous sites on the patient's upper arm or leg because as taught by Berd (1988) this is a conventional means for administering the melanoma cancer vaccine and would have provided an effective route of administration.

With respect to claims 24, 25, 28 and 29, the claims of '004 do not specifically recite administering the vaccine to post-surgical melanoma patients or to stage 4 melanoma patients. However, Berd (1988; see, e.g., page 340) teaches administering

melanoma vaccines to patients post-surgically and to patients with extensive metastatic disease. Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have administered the hapten-conjugated melanoma to patients post-surgically and to stage 4 melanoma patients in order to have provided an effective means of treatment for those patients most in need of therapy.

With respect to claim 30, the claims of '004 do not specifically recite administering the vaccine every 4 weeks. However, Berd (1988; page 340) teaches repeating the vaccine treatment every 28 days, for up to 15 cycles of administration. Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have intradermally administered the hapten-conjugated melanoma vaccine every 4 weeks because this would have boosted the response to the vaccine and thereby would have increased the effectiveness of the therapy.

With respect to claims 21, 22 and 31, the claims of '004 do not recite that the melanoma cells are cryopreserved. However, Berd (1988; page 340) teaches that the tumor masses are removed from the patient and tumor cells are cryopreserved in liquid nitrogen until needed. Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have used cryopreserved autologous melanoma cells in the method and compositions of '004 because this would have provided a more convenient means of administering the therapy since such cells could be frozen and stored and then administered at 4 week intervals.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

18. Applicant is reminded of the continuing obligation under 37 CFR 1.178(b), to timely apprise the Office of any prior or concurrent proceeding in which Patent No. 5,290,551 is or was involved. These proceedings would include interferences, reissues, reexaminations, and litigation.

19. Applicant is notified that any subsequent amendment to the specification and/or claims must comply with 37 CFR 1.173(b).

Applicant is further reminded of the continuing obligation under 37 CFR 1.56, to timely apprise the Office of any information which is material to patentability of the claims under consideration in this reissue application.


These obligations rest with each individual associated with the filing and prosecution of this application for reissue. See also MPEP §§ 1404, 1442.01 and 1442.04.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carla Myers whose telephone number is (571) 272-0747. The examiner can normally be reached on Monday-Thursday from 6:30 AM-5:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (571)-272-0745.

The fax phone number for the organization where this application or proceeding is assigned is (571)-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at (866)-217-9197 (toll-free).

Carla Myers
May 9, 2005


CARLA J. MYERS
PRIMARY EXAMINER